Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6F1PU)

Drug Name
Vortioxetine Drug Info
Synonyms
VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004
Cross-matching ID
PubChem CID
9966051
ChEBI ID
CHEMBL2104993
CAS Number
CAS 508233-74-7
TTD Drug ID
D03WEX
VARIDT Drug ID
DR01102
INTEDE Drug ID
DR1712
ACDINA Drug ID
D00735

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 1.96 0.00e+0 19/20 (95%) MSMO1;TM7SF2;CYP51A1;...
Antigen processing and presentation 1.93 6.30e-3 60/78 (76.92%) CTSB;HSP90AA1;CD8B;...
Th1 and Th2 cell differentiation 1.92 8.40e-3 80/92 (86.96%) IL2RG;NFATC3;CD3D;...
Terpenoid backbone biosynthesis 1.88 9.45e-3 18/22 (81.82%) IDI1;HMGCS1;HMGCR;...
Type I diabetes mellitus 1.80 2.77e-2 38/43 (88.37%) ICA1;HLA-DMB;HLA-B;...
T cell receptor signaling pathway 1.80 2.31e-2 93/104 (89.42%) CDC42;NFATC3;CD3D;...
Th17 cell differentiation 1.75 3.24e-2 95/107 (88.79%) IL2RG;HSP90AA1;NFATC3;...
Graft-versus-host disease 1.75 2.84e-2 32/42 (76.19%) HLA-DMB;HLA-B;IFNG;...
Primary bile acid biosynthesis 1.74 3.08e-2 15/17 (88.24%) AMACR;CYP46A1;SCP2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H